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ABSTRACT
Introduction: The 21-gene Recurrence Score
assay (Oncotype DX, Genomic Health, Inc.) is a
validated predictor of recurrence risk/
chemotherapy benefit in patients with
estrogen receptor-positive (ER?) early-stage
breast cancer treated with endocrine therapy.
The Prosigna assay (NanoString Technologies
Inc.) is a validated prognosticator in
postmenopausal patients with low-risk ER?
early-stage breast cancer treated with
endocrine therapy. The assays were
analytically/clinically developed and validated
differently. This study focused on comparing
recurrence risk estimates as determined by these
assays and is the first blinded comparison of
these assays on matched patient samples.
Methods: Sequential breast cancer specimens
from postmenopausal, node-negative, ER?
patients treated at the Marin General Hospital
were analyzed: first by the 21-gene assay then by
the Prosigna assay in an independent lab
blinded to the Recurrence Score results.
Results: The final analysis included 52 patients.
Correlation between the Recurrence Score and
the Prosigna assay results was poor (r = 0.08).
Agreement between risk classifications based on
these assays was 54%; 4/7 of patients classified
as high risk by the Prosigna assay had low
Recurrence Score results. Two tumors with high
Recurrence Score results had low ER expression
(close to positivity threshold); both of which
had a low/intermediate Prosigna assay result.
The Prosigna assay classified 73.1% and 23.1%
of samples as luminal A and luminal B,
respectively. A range of Recurrence Score
results was observed within the subtypes; 83%
of luminal B samples had a low Recurrence
Score result.
Conclusion: Consistent with prior comparisons
between the 21-gene and other genomic assays,
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our study demonstrated substantial differences
in the way patients are risk stratified, suggesting
that the different assays are not
interchangeable.
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INTRODUCTION
The last decade has seen a dramatic increase in
the use of genomic assays in routine clinical
practice for patients with early-stage breast
cancer. These genomic assays differ in the
technological platforms, development,
analytical and clinical validation as well as the
gene sets that are included in the algorithm.
Furthermore, the patient cohorts included in
the clinical validation studies differ
substantially ranging from small single-center
cohorts of convenience samples to large cohorts
from randomized clinical trials with long-term
clinical outcomes and archived tissue.
The current study focused on two such
genomic assays: The 21-gene Recurrence
Score assay (Oncotype DX, Genomic Health,
Inc., Redwood City, CA, USA) and the Prosigna
assay (NanoString Technologies Inc., Seattle,
WA, USA). The 21-gene assay is a quantitative
reverse transcriptase polymerase chain reaction
(qRT-PCR)-based multigene assay that has been
clinically validated as a prognosticator in
estrogen receptor (ER)-positive early-stage
breast cancer treated with endocrine therapy
as well as a predictor of the likelihood of
chemotherapy benefit (i.e., patients with a
high score have a greater likelihood of benefit
and patients with a low score would be expected
to have little to no benefit) [1–7]. The
Recurrence Score result provides a quantitative
estimate of the 10-year risk of distant recurrence
based on the individual patient’s tumor. The
21-gene assay has been incorporated into the
consensus statement of the IMPAKT (IMProving
care And Knowledge through Translational
research) 2012 Working Group (as having
convincing evidence on analytical and clinical
validity) [8] and into major international
guidelines including those by the National
Comprehensive Cancer Network, the
American Society of Clinical Oncology, the
European Society for Medical Oncology, and St.
Gallen, and a recommendation by the National
Institute for Health and Care Excellence (NICE)
in the UK [9–13].
The Prosigna assay is based on PAM50, a
50-gene microarray profile originally developed
for research purposes to assess the phenotypic
diversity of breast tumors and corresponding
diversity in gene expression [14, 15]. The
Prosigna assay has been validated as a
prognosticator in clinically low-risk,
postmenopausal patients with ER-positive
early-stage breast cancer treated with endocrine
therapy [16–18]. To date, the Prosigna assay has
not been shown tobe predictive of chemotherapy
benefit. The IMPAKT 2012 Working Group did
not find the analytical/clinical evidence for this
assay to be convincing [8] and the assay is
currently not acknowledged in international
guidelines as having data supporting prediction
of chemotherapy benefit [9–13].
Increasingly, there is a misconception that
all the risk-stratifying assays provide similar
information that can be used interchangeably
for prognostication and treatment decisions.
There have now been multiple reports
comparing the 21-gene assay with the 70-gene
assay (MammaPrint, Agendia, Inc. Amsterdam,
The Netherlands), the five-antibody assay
(Mammostrat, Clarient, Inc., Aliso Viejo, CA,
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USA), and the 12-gene assay (EndoPredict,
Sividon Diagnostics, Cologne, Germany) that
have clearly shown that the assays stratify
patients differently [19–22].
We hypothesized that the 21-gene assay and
the Prosigna assay also stratify patients
differently. To test this hypothesis, we
performed a prospectively designed
comparison between these assays using the




The study was prospectively designed to analyze
archival samples from patients with ER-positive
early-stage breast cancer. The sample size was
calculated to be 70 samples based on the
number of samples needed to assess the
concordance between the two assays in terms
of risk stratification and accounting for
approximately 20% dropout. The assays were
run in independent laboratories and each
blinded to the results of the other. The
primary objective of the study was to assess
the agreement in risk stratification between the
two assays. Secondary objectives included
calculating the correlation between results of
the two assays; assessing ER expression within
Prosigna risk groups; and determining the
distribution of the Recurrence Score and
Prosigna results within luminal subtypes as
defined by the Prosigna Breast Cancer Intrinsic
Classifier.
The study was reviewed and approved by an
institutional review board and was granted a
waiver for obtaining patient consent since there
were no patient outcomes included in the
analysis. All samples were de-identified for
patient specific information.
Patients and Samples
Consecutive FFPE breast cancer samples (all
excisional specimens) were obtained from
Marin Medical Laboratories (Novato, CA,
USA), that serves as the tissue repository for
the Marin General Hospital and provides tissue
samples (from patients originally seen at the
Marin clinics) for research purposes. For this
study, tissue samples that were made available
were from patients seen between 2000 and
2001, as for them, the assay results were not
going to impact treatment decisions. In
addition, the following inclusion criteria were
met: Postmenopausal, ER-positive (by
immunohistochemistry [IHC] or RT-PCR) and
HER2 negative (by IHC or fluorescence in situ
hybridization [FISH]). The 21-gene assay was
performed at the Genomic Health laboratory
(Redwood City, CA, USA), and the Recurrence
Score result, the predefined Recurrence Score
risk group (low:\18; intermediate: 18–30; high
C31) [1], and quantitative ER, progesterone
receptor (PR), and HER2 gene scores were
reported. The cut-off values used for ER and
PR positivity were 6.5 and 5.5 units,
respectively. For HER2, the positive cut-off was
C11.5 units, equivocal ranged from 10.7 to 11.4
units, and the negative cut-off was\10.7 units.
Samples were excluded from the analysis if they
were ER-negative, if there was insufficient
tumor material for testing, or if the patients
were node-positive or premenopausal.
FFPE-tumor samples prepared per Prosigna
protocol were sent to an independent
laboratory in Europe that was blinded to the
Recurrence Score results, for obtaining the
Prosigna score for risk group (for
node-negative patients: low: 0–40;
intermediate: 41–60; high: 61–100) [23], and
intrinsic subtype determination which is not
currently available in the US.
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Statistical Considerations
All analysesweredescriptive. Two-way frequency
tables and exact 95% Clopper-Pearson
confidence intervals [CIs] were used to assess
the agreement between risk group classifications
based on the two assays. Spearman correlation
between the Recurrence Score and the Prosigna
results was calculated. SAS Enterprise guide
version 5.1 (SAS Institute Inc., Cary, NC, USA)
was used for the analysis.
RESULTS
Patients and Samples
A total of 70 consecutive samples were obtained
from Marin Medical Laboratories. Samples from
18 patients were excluded: four were ER-negative,
six were node-positive, five were premenopausal,
and three yielded insufficient tumor RNA for the
21-gene assay. Thenumberof samples included in
the final analysis cohort was 52.
More than half of the samples (55.8%) were
from patients aged C70 years. The majority of
tumors were invasive ductal carcinoma (73.1%),
B2 cm in size (78.9%), and grade 1 or 2 (90.4%;
Table 1).
Distribution of Recurrence Score
and Prosigna Results
The distribution of the Recurrence Score and
the Prosigna results exhibited marked
differences as there were more patients
classified as low risk and fewer patients
classified as intermediate or high risk by the
Recurrence Score result compared to the
Prosigna result (Fig. 1). The median Recurrence
Score result was 12 (range 0–36) with 37
(71.2%), 12 (23.1%), and 3 (5.8%) in the low,
intermediate, and high Recurrence Score risk
groups, respectively. The median Prosigna score
was 39 (range 0–88) with 28 (53.8%), 17
(32.7%), and 7 (13.5%) samples in the low,
intermediate, and high risk groups, respectively
(Fig. 1a, b).
Comparison of Risk Scores
Overall agreement for risk classification based on
the Recurrence Score and the Prosigna score
results was 53.8% (Table 2). Thirty-seven
Table 1 Baseline patient and tumor characteristics
Characteristics N5 52
Age category, n (%)
50–59 years 9 (17.3)
60–69 years 14 (26.9)
C70 years 29 (55.8)
Tumor size category, n (%)
T1a (0–0.5 cm) 0 (0.0)
T1b (0.6–1.0 cm) 17 (32.7)
T1c (1.1–2.0 cm) 24 (46.2)
T2 (2.1–5.0 cm) 11 (21.2)
Tumor size, cm
Mean (SD) for T1 1.2 (0.4)
Mean (SD) for T2 3.1 (0.8)
Histology, n (%)
Invasive ductal carcinoma 38 (73.1)
Invasive lobular carcinoma 13 (25.0)
Mixed 1 (1.9)
Tumor grade category, n (%)
Grade 1 24 (46.2)
Grade 2 23 (44.2)
Grade 3 5 (9.6)
SD Standard deviation
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patients had a low Recurrence Score result versus
28patientswith a lowProsigna score. Twenty-two
patients had a low score from both assays.
The correlation between the Recurrence
Score and the Prosigna score results was poor
(Fig. 1c; r = 0.08; 95% CI, -0.2 to 0.35;
Spearman correlation). There were only three
patients with a high Recurrence Score result
versus seven with a high Prosigna score. Of
note, 57.1% (4/7) of the patients classified as
high risk by the Prosigna assay, were classified as
low risk by the Recurrence Score result. Of the
three patients with high Recurrence Score
results, only one patient was high by the
Prosigna assay, the other two were low and
intermediate (Fig. 1c).
Quantitative ER Expression
Evaluation of quantitative ER expression (by
RT-PCR) showed a wide range of expression
within each Prosigna score risk group (Fig. 2).
All four patients classified as high risk by the
Prosigna assay and low risk by the Recurrence
Score result exhibited high ER expression. In
addition, there were two patients whose ER
expression was close to the positivity threshold
with high Recurrence Score results that were
low or intermediate by the Prosigna assay.
Recurrence Score and Prosigna Results
Within Intrinsic Subtypes
The Prosigna assay classified 38 (73.1%) of the
samples as luminal A and 12 (23.1%) as luminal
B. Two samples were non-luminal (1 Her2
enriched and 1 basal like). As expected (since
intrinsic subtype determination and Prosigna
score calculations are interrelated), all samples
identified as luminal A were characterized as
low or intermediate risk according to the
Prosigna assay, whereas all samples identified
as luminal B were characterized as intermediate
or high risk. However, in both the luminal A
and B samples there was a range of Recurrence
Score results (Fig. 3). Specifically, among the 38
luminal A samples, 1 (2.6%) had a high
Fig. 1 Distribution of scores and correlation between
assays (N = 52). a Distribution of Recurrence Score results
in the cohort; b distribution of Prosigna results in the
cohort; c correlation between the Recurrence Score and
the Prosigna results in node-negative postmenopausal
patients
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Recurrence Score result, and among the 12
luminal B samples, 10 (83.3%) had low
Recurrence Score results.
DISCUSSION
The current analysis, the first prospectively
designed comparison between the Recurrence
Score and Prosigna assays, shows that these
assays classify patients differently. Specifically,
the study showed a wide variation in
Recurrence Score results within each Prosigna
risk category and a poor correlation between the
Recurrence Score and the Prosigna results, with
more than half of the patients classified as high
risk by the Prosigna assay being classified as low
risk by the Recurrence Score result. This study is
also the first formal/pre-specified analysis of the
distribution of Recurrence Score results within
the PAM50-defined luminal subtypes and
showed that not all luminal B patients have
high Recurrence Score results. Of note, the
Prosigna assay was optimized to not have any
high scores in luminal A subtype and no low
scores in luminal B subtype. The impact of this
on the distribution of the Recurrence Score
results within luminal subtypes is not known.
Our findings are generally consistent with
those of Dowsett et al. [17] who compared the
Recurrence Score results and the Risk of
Recurrence (ROR) score (the precursor to the
Prosigna assay) in the TransATAC study and
showed an agreement in risk group assignment
(in node-negative patients; n = 739) of 58%,
which is similar to the 53% observed here. In
Table 2 Agreement in risk group assignment between Recurrence Score and Prosigna results in postmenopausal,
node-negative, ER-positive patients (N = 52)
Recurrence Score risk groupa
Low Intermediate High Total
Prosigna risk groupb
Low 22 (79%), 95% CI 59–92% 5 (18%), 95% CI 6–37% 1 (4%), 95% CI 0–18% 28
Intermediate 11 (65%), 95% CI 38–86% 5 (29%), 95% CI 10–56% 1 (6%), 95% CI 0–29% 17
High 4 (57%), 95% CI 18–90% 2 (29%), 95% CI 4–71% 1 (14%), 95% CI 0–56% 7
Total 37 12 3 52
CI Conﬁdence interval
a Risk classiﬁcations by the Recurrence Score result. Low:\18; intermediate: between 18 and 30; high: C31
b Risk classiﬁcations by the Prosigna assay for node-negative patients. Low,\40; intermediate, between 41 and 60; high,
between 61 and 100
Fig. 2 Quantitative ER expression by Recurrence Score
and Prosigna results (N = 52). The horizontal line at 6.5
represents the threshold for ER positivity; the dashed lines
within each Prosigna risk group represent the median
within each Recurrence Score group. CT threshold cycle,
ER Estrogen receptor
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the TransATAC study samples, the ROR score
identified fewer intermediate patients (the risk
thresholds used there were \10% for low,
10–20% for intermediate and [20% for high
risk). In our analysis, where the risk groupings
provided on each patient report were used, the
Prosigna assay yielded more intermediate risk
results (17) than the Recurrence Score assay (12)
[17]. Notably, in the Dowsett et al. [17] study,
the ROR assay was performed on residual RNA
extracted by Genomic Health in an earlier study
(i.e., samples were microdissected and the RNA
was extracted using Genomic Health
proprietary methods), which may be relevant,
since RNA extraction methods have been
shown to impact gene expression analysis [24].
Indeed, the results in the validation study
conducted in TransATAC were substantially
different from those reported for the
validation study conducted in the ABCSG-8
trial with the risk of recurrence being
approximately twofold higher in patients with
a high and intermediate ROR scores [16, 17];
possibly due to different RNA extraction
methods, differences in patient populations, or
both. Furthermore, in the Dowsett et al. [17]
analysis, the cut points for the Recurrence Score
risk groups were not based on the validated
values defining the Recurrence Score risk groups
(\18, 18–30, C31), but rather percentage risk
based on the ROR categories (\10%, 10–20%,
[20%).
Our results are also consistent with findings
from previous studies comparing Recurrence
Score-based risk assessments with risk
assessment based on other assays, including
the 70-gene assay, the five-antibody assay, and
the 12-gene assay [20–22], as well as with recent
findings from the prospective OPTIMA pilot
feasibility study which compared risk
assignments between the Recurrence Score
assay, the 70-gene assay, the Prosigna assay,
IHC4, and IHC4 AQUA (Genoptix, Carlsbad,
CA, USA) as part of the feasibility of using a
Fig. 3 Distribution of Recurrence Score and Prosigna results within luminal A and luminal B subtypes
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genomic profile assay for treatment decisions
[25]. These studies revealed consistent
differences in risk classification between the
assays. Most notably that the Recurrence Score
assay consistently classifies fewer patients as
high risk. These differences may be due to the
different platforms (e.g., array vs. RT-PCR),
different genes included in the assays, and
differences in clinical validation (e.g., using
legacy trials with long-term follow-up vs.
convenience samples where patients were not
treated uniformly) [1–6, 16–18]. To date, the
Recurrence Score assay is the only one shown to
predict the likelihood of chemotherapy benefit
(i.e., which patients are likely to benefit from
adding chemotherapy to endocrine therapy and
which are unlikely to derive benefit) [2, 4].
Our studywas able to identifypatientswithhigh
Prosigna score results and low Recurrence Score
results. Based on the Recurrence Score validation
studies [2, 4], suchpatients are likely tohave little to
no chemotherapy benefit. Furthermore, in our
study, these patients had high ER expression
levels, and thus were likely to derive substantial
benefit from endocrine therapy alone which is of
clinical relevance since the Prosigna assay was
developed in untreated patients.
Of note, the 5-year outcomes for the study
arm of 1626 ER-positive, node-negative patients
with a Recurrence Score result\11 enrolled in
the TAILORx study (the largest prospective
adjuvant trial to date) were recently published
in the New England Journal of Medicine and
confirmed the very low distant recurrence risk
for patients treated with endocrine therapy
alone (rate of freedom from distant recurrence
at 5 years: 99.3%) [7]. This 5-year distant
recurrence rate in this contemporary cohort is
even lower than expected based on the prior
experience reported in the validation studies
[26]. Furthermore, with a recurrence rate so low,
it is certain that patients with a low Recurrence
Score result will not derive additional benefit
from the addition of chemotherapy.
Additional clinical relevance of our findings
pertains to the use of intrinsic subtypes
(luminal A or B) to assess recurrence risk and
make treatment decisions. To date, there has
not been a standardized method to determine
luminal subtype, aside from the original PAM50
microarray. In addition, while the luminal
subtypes differ prognostically, there is no
evidence that luminal subtyping is predictive
of chemotherapy benefit. In our study, 83% of
the luminal B patients had low Recurrence Score
results, and are therefore likely to have little to
no benefit from chemotherapy. Furthermore, in
our study, these patients also had high ER
expression, and thus, are expected to benefit
substantially from endocrine therapy alone, as
noted above.
While this is the first truly blinded
head-to-head comparison of the Recurrence
Score and Prosigna assays, the study does have
some limitations. The study was designed to
compare the Recurrence Score and Prosigna
assays, focusing solely on risk estimates.
Discerning the impact of the differences in risk
stratification on treatment decisions and
clinical outcomes was beyond the scope of the
current study (as outcome data were not
available). In addition, it is a single-center
study with a relatively small sample size.
Consequently, subgroup analysis exploring the
discordance between the assays in subgroups of
patients based on tumor/patient characteristics
such as age, grade, and tumor size was not
possible.
CONCLUSIONS
The consistency of the results from this
comparison of the Recurrence Score and
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Prosigna assays and prior studies showing that
different assays vary substantially in risk
assignation, indicates that genomic assays
cannot be used interchangeably. In particular,
since the correlation of the Recurrence Score
results (which is the only assay validated to
predict chemotherapy benefit) and the results of
other assays is poor-to-modest, it cannot be
assumed that the other assays are also predictive
of chemotherapy benefit. As new assays become
available, it will be critically important to
understand the differences between the assays
to comprehend the implications for clinical
practice.
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